J&J
Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment
J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.
Johnson & Johnson Expands Dermatology Portfolio with $850M Acquisition of Proteologix
Johnson & Johnson, J&J, Proteologix, atopic dermatitis, bispecifics, pipeline, acquisition, $850M
Revolutionizing Cardiac Mapping: J&J’s Biosense Webster Integrates AI into Carto 3 System
J&J, Biosense Webster, AI, Carto 3 system, cardiac mapping, heart mapping, electrophysiology, medical technology, healthcare innovation.
Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints
Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.
Projected $270 Billion Orphan Drug Market by 2028: A Comprehensive Analysis of Leading Players J&J, Vertex, and Roche
Orphan drugs, rare diseases, J&J, Vertex, Roche, market growth, 2028, Evaluate
AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline
AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor